The epidemiology of prostate cancer

Urologic Clinics of North America

Volumn 30, Issue 2, 2003, Pages 209-217

  Boyle, Peter ^a   Severi, Gianluca ^a   Giles, Graham G ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANDROSTANOLONE; CYCLOOXYGENASE 2 INHIBITOR; LYCOPENE; PROSTATE SPECIFIC ANTIGEN; SELENIUM; SOMATOMEDIN C; VITAMIN D; ZINC;

ALCOHOL CONSUMPTION; ANTIGEN DETECTION; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; DIET; DIET SUPPLEMENTATION; EARLY DIAGNOSIS; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; GENE MUTATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; LIFESTYLE; MASTECTOMY; OCCUPATION; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING;

EID: 0037407142     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00181-7     Document Type: Review

References (73)

1. Yatani R, Chigusa I, Akazaki K, et al. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982;29:611-6.
2. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents, Vol 7, Lyon, France; International Agency for Research on Cancer; 1997.
3. Clinton SK, Giovannucci E. Diet, nutrition, and prostate cancer. Annu Rev Nutr 1998;18:413-40.
4. Chan JM, Stampfer MJ, Giovannucci EL. What causes prostate cancer? A brief summary of the epidemiology. Semin Cancer Biol 1998;8:263-73.
5. Ross RK, Schottenfeld D. Prostate cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. 2nd edition. New York: Oxford University Press; 1996. p. 1180-206.
6. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 2001;23(1):3-13.
7. Newcomer LM, Stanford JL, Blumenstein BA, et al. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol 1997;158:1127-30.
8. Boyle P, Severi G. Epidemiology of prostate cancer chemoprevention. Eur Urol 1999;35(5-6):370-6.
9. Tarone RE, Chu KC, Brawley O. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000;11(2):167-70.
10. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000;355(9217):1788-9.
11. Lesko SM, Rosenberg L, Shapiro S. Family history and prostate cancer risk. Am J Epidemiol 1996;144:1041-7.
12. Hopper JL, Carlin JB. Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am J Epidemiol 1992;136:1138-47.
13. Ostrander EA, Stanford JL. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 2000;67:1367-75.
14. Peto J. Genetic predisposition to cancer. In: Cairns J, Lyon JL, Skolnick M, editors. Cancer incidence in defined populations (Banbury Report no. 4). Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1980. p. 203-13.
15. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-70.
16. Xue W, Irvine RA, Yu MC, et al. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate specific antigen loci. Cancer Res 2000;60:839-41.
17. Jaffe JM, Malkowicz SB, Walker AH, et al. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 2000;60:1626-30.
18. Walker AH, Jaffe JM, Gunasegaram S, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Hum Mutat 1998;12:289.
19. Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in US physicians. Cancer Epidemiol Biomarkers Prev 1998;242:467-73.
20. Kelada SN, Kardia SL, Walker AH, et al. The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: genotype-environment interactions with smoking. Cancer Epidemiol Biomarkers Prev 2000;9:1329-34.
21. Rebbeck TR, Walker AH, Zeigler-Johnson C, et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000;67:1014-9.
22. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998;44:705-23.
23. Santen RJ. Endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992;75:685-9.
24. Bentel JM, Tilley WD. Androgen receptors in prostate cancer. J Endocrinol 1996;151:1-11.
25. Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998;58:4497-504.
26. Choong CS, Kemppainen JA, Zhou Z-X, et al. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol 1996;10:1527-35.
27. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-6.
28. Moghrabi N, Hughes E, Dunaif A, et al. Deleterious missense mutations and silent polymorphism in the human 17β-hydroxysteroid dehydrogenase 3 gene (HSD17B3). J Clin Endocrinol Metab 1998;83:2855-60.
29. Issa LL, Leong GM, Eisman JA. Molecular mechanism of vitamin D receptor action. Inflamm Res 1998;47:451-75.
30. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-71.
31. Taylor JA, Hirvonen A, Watson M, et al. Association of prostate cancer with vitamin D receptorgene polymorphism. Cancer Res 1996;56:4108-4110.
32. Corder EH, Friedman GD, Vogelman JH, et al. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biol Prev 1995;4:655-9.
33. Nickerson T, Huynh H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 1999;160:223-9.
34. Miyao M, Hosoi T, Inoue S, et al. Polymorphism of insulin-like growth factor I gene and bone mineral density. Calcif Tissue Int 1998;63:306-11.
35. Mullis PE, Patel MS, Brickell PM, et al. Constitutionally short stature: analysis of the insulin-like growth factor-I gene and the human growth hormone gene cluster. Pediatr Res 1991;29:412-5.
36. Rosen CJ, Kurland ES, Vereault D, et al. Association between IGF 1 and a simple sequence repeat in the IGF 1 gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.
37. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. J Natl Cancer Inst 1999;91(5):414-28.
38. Norrish AE, Ferguson LR, Knize MG, et al. Heterocyclic amine content of cooked meat and risk of prostate cancer. J Natl Cancer Inst 1999;91:2038-44.
39. Liang T, Liao S. Inhibition of steroid 5α-reductase by specific aliphatic unsaturated fatty acids. Biochem J 1992;285:557-62.
40. Zhou JR, Blackburn GL. Bridging animal and human studies: what are the missing segments in dietary fat and prostate cancer? Am J Clin Nutr 1997;66:1572S-80S.
41. Norrish AE, Jackson RT, McRae CU. Nonsteroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77:511-5.
42. Ghosii J, Myers C. Arachidonic acid metabolism and cancer of the prostate. Nutrition 1998;14:48-9.
43. Chan JM, Giovannucci EL. Vegetables, fruits, associated micronutrients, and risk of prostate cancer. Epidemiol Rev 2001;23:82-6.
44. Clinton SK, Emenhiser C, Schwartz SJ, et al. Cistrans lycopene isomers, carotenoids, and retinol in the human prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:823-33.
45. Rautalahti M, Albanes D, Virtamo J, et al. Betacarotene did not work: aftermath of the ATBC study. Cancer Lett 1997;114:235-6.
46. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92(24):2018-23.
47. Griffiths K, Denis L, Turkes A, Morton MS. Possible relationship between dietary factors and pathogenesis of prostate cancer. Int J Urol 1998;5:195-213.
48. Barnes S. Role of phytochemicals in prevention and treatment of prostate cancer. Epidemiol Rev 2001;23(1):102-5.
49. Chhabra SK, Yang CS. Tea and prostate cancer. Epidemiol Rev 2001;23:106-9.
50. Kristal AR, Stanford JL, Cohen JH, et al. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8:887-92.
51. Putnam SD, Cerhan JR, Parker AS, et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol 2000;10:361-9.
52. Liu SE, Lee IM, Linson P, et al. A prospective study of physical activity and risk of prostate cancer in US physicians. J Epidemiol 2000;29:29-35.
53. vom Saal FS, Timms BG, Montano MM, et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Nat Acad Sci 1997;94:2056-61.
54. Clarke G, Whittemore AS. Prostate cancer risk in relation to anthropometry and physical activity: the National Health and Nutrition Examination Survey Epidemiological Follow-Up Study. Cancer Epidemiol Biomarkers Prev 2000;9:875-81.
55. Lund Nilsen TI, Johnsen R, Vatten LJ. Socioeconomic and lifestyle factors associated with the risk of prostate cancer. Br J Cancer 2000;82:1358-1363.
56. Severson RK, Grove JS, Nomura AMY, Stemmerman GN. Body mass and prostate cancer: a prospective study. BMJ 1988;297:713-5.
57. Ewings P, Bowie C. A case-control study of cancer of the prostate in Somerset and east Devon. Br J Cancer 1996;74(4):661-6.
58. Hayes RB, Pottern LM, Strickler H, et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000;82(3):718-25.
59. Andersson SO, Baron J, Bergstrom R, Lindgren C, Wolk A, Adami HO. Lifestyle factors and prostate cancer risk: a case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 1996;5(7):509-13.
60. Hsieh CC, Thanos A, Mitropoulos D, Deliveliotis C, Mantzoros CS, Trichopoulos D. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 1999;80(5):699-703.
61. Strickler HD, Goedert JJ. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev 2001;23(1):144-51.
62. Rotkin ID. Studies in the epidemiology of prostatic cancer: expanded sampling. Cancer Treat Rep 1977;61(2):173-80.
63. Fincham SM, Hill GB, Hanson J, Wijayasinghe C. Epidemiology of prostatic cancer: a case-control study. Prostate 1990;17(3):189-206.
64. Ross RK, Deapen DM, Casagrande JT, et al. A cohort study of mortality from cancer of the prostate in Catholic priests. Br J Cancer 1981;43:233-5.
65. Colditz G. Consensus conference: smoking and prostate cancer. Cancer Causes Control 1996;7:560-2.
66. Lumey LH. Prostate cancer and smoking: a review of case-control and cohort studies. Prostate 1996;29:249-60.
67. Giovannucci E, Rimm EB, Ascherio A, et al. Smoking and risk of total and fatal prostate cancer in United States Health professionals. Cancer Epidemiol Biomarkers Prev 1999;8:277-82.
68. Lotufo PA, Lee IM, Ajani UA, et al. Cigarette smoking and risk of prostate cancer in the Physicians' Health Study. Int J Cancer 2000;87:141-4.
69. Breslow RA, Weed DL. Review of epidemiologic studies of alcohol and prostate cancer: 1971-1996. Nutr Cancer 1998;30:1-13.
70. Lumey LH, Pittman B, Wynder EL. Alcohol use and prostate cancer in U.S. whites: no association in a confirmatory study. Prostate 1998;36:250-55.
71. Villeneuve PJ, Johnson KC, Krieger N, Mao Y. Risk factors for prostate cancer: results from the Canadian National Enhanced Cancer Surveillance System. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control 1999;10:355-67.
72. Schuurman AG, Goldbohm RA, van den Brandt PA. A prospective study on consumption of alcoholic beverages in relation to prostate cancer incidence (The Netherlands). Cancer Causes Control 1999;10:597-605.
73. Rautalahti M, Albanes D, Virtamo J, et al. Betacarotene did not work: aftermath of the ATBC study. Cancer Lett 1997;114:235-6.